OBJECTIVE: To systematically review the biological activities of pectin synthesised MNPs (Pe-MNPs).
METHODS: The databases Springer Link, Scopus, ScienceDirect, Google Scholar, PubMed, Mendeley, and ResearchGate were systematically searched from the date of their inception until 10th February 2020. Pectin, green synthesis, metallic nanoparticles, reducing agent and biological activities were among the key terms searched. The data extraction was focussed on the biological activities of Pe-MNPs and reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations for systematic reviews.
RESULTS: A total of 15 studies outlined 7 biological activities of Pe-MNPs in the only three metals that have been explored, namely silver (Ag), gold (Au) and cerium oxide (CeO2). The activities reported from the in vitro and in vivo studies were antimicrobial (9 studies), anticancer (2 studies), drug carrier (3 studies), non-toxic (4 studies), antioxidant (2 studies), wound healing (1 study) and anti-inflammation (1 study).
CONCLUSIONS: This systematic review demonstrates the current state of the art of Pe-MNPs biological activities, suggesting that Ag and Au have potent antibacterial and anticancer/chemotherapeutic drug carrier activity, respectively. Further in vitro, in vivo, and clinical research is crucial for a better understanding of the pharmacological potential of pectin synthesised MNPs.
METHODS: Health policy experts from the public and private sectors were asked to participate in a survey to explore the current and future status of HTA implementation in Jordan. Semistructured interviews with senior policy makers supported by literature review were conducted to validate survey results and make recommendations for specific actions.
RESULTS: Survey and interview results indicated a need for increased HTA training, including both short courses and academic programs and gradually increasing public funding for technology assessment and appraisal. Multiple HTA bodies with central coordination can be the most feasible format of HTA institutionalization. The weight of cost-effectiveness criterion based on local data with published reports and explicit decision thresholds should be increased in policy decisions of pharmaceutical and nonpharmaceutical technologies.
CONCLUSION: Currently, HTA has limited impact on health policy decisions in Jordan, and when it is used to support pharmaceutical reimbursement decisions, it is mainly based on results from other countries without considering transferability of international evidence. Policy makers should facilitate HTA institutionalization and use in policy decisions by increasing the weight of local evidence in HTA recommendations.